Business Wire

CA-XSOLLA

17.7.2024 14:01:31 CEST | Business Wire | Press release

Share
Xsolla Launches Instant Access to Their Core Solutions: Game Sales, Launcher, and Cloud Gaming, to Provide Game Developers With Quick Access to Generating Revenue

Xsolla, a global video game commerce company, announces the launch of Xsolla Instant Game Sales, Instant Launcher, and Instant Cloud Gaming following the release of Instant Web Shop in March 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240717305685/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Xsolla)

We have listened to developers express their primary challenges—resource allocation is crucial, yet many struggle to quickly go live with their games and offerings. In response, our streamlined approach facilitates seamless integration and provides developers of any size with instant tools to open new revenue streams for their games. Xsolla partners with game developers and studios of all sizes, offering a swift process to sign license agreements, integrate solutions, and generate revenue promptly, accelerating go-to-market time with direct-to-consumer solutions.

David Stelzer, President of Xsolla, comments: "Xsolla Instant Solutions suite enables developers to quickly and easily launch new monetization channels for their games, attract new paying audiences, and boost revenue by leveraging Xsolla’s comprehensive suite of solutions. We aim to help developers unlock new revenue opportunities while reducing time to market to one day, similar to what we did with the Instant Web Shop launch earlier this year."

Instant Web Shop

Instant Web Shop enables game developers to swiftly set up a fully operational online store for their mobile games, seamlessly transforming a simple link into a revenue-generating platform. This solution increases awareness of the advantages of online purchases and facilitates an effortless shift to a robust LiveOps monetization system, enhancing user engagement and maximizing revenue streams. Instant Web Shop also helps game developers generate more value and purchases with personalization, limited-time offers, promotions, and deep linking.

For more information about Xsolla Instant Web Shop or to sign up, visit: xsolla.pro/ws1

Instant Game Sales

Instant Game Sales empowers developers to create store pages and initiate direct-to-consumer sales by importing content directly from Steam and Epic Game Store. This enables developers to integrate these offerings into their Game Sales page. It facilitates immediate game key sales during pre-orders and pre-launch phases, game releases, and seasonal promotions.

For more information about Xsolla Instant Game Sales or to sign up, visit: xsolla.pro/gs1

Instant Launcher

The Instant Launcher is receiving a significant update to enhance its content delivery system. Developers can import content directly from Steam and Epic Game Store to access a pre-designed launcher app with pre-created design, details, and assets to enable instant direct-to-consumer distribution of their games. Instant Launcher benefits games at any release stage, powering test flights during pre-launch, upcoming launch, and further game monetization. With Launcher, developers can easily directly engage with their audience while cross-promoting their games inside one gaming hub, decreasing the average cost per lead.

For more information about Xsolla Instant Launcher or to sign up, visit: xsolla.pro/launcher1

Instant Xsolla Cloud Gaming

Instant Cloud Gaming offers a self-serve solution for seamless game distribution by rapidly launching a branded cloud gaming platform in as little as 30 minutes to 24 hours. Xsolla Cloud Gaming enables developers to engage directly with their audience by offering pre-launch testing, sharing early versions of their games with the community, and providing the opportunity to demo the game directly from the landing page. Scaling game access to any device ensures quick access to new revenue streams and guarantees reaching more players globally.

For more information about Xsolla Instant Cloud Gaming or to sign up, visit: xsolla.pro/cg1

About Xsolla

Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.

For additional information and to learn more, please visit: xsolla.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240717305685/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye